Home

RICHARD G VINCENT

CIK 1269341 · Chief Financial Officer · last filed 2026-08-27

RICHARD G VINCENT is a Chief Financial Officer who has filed 30 SEC Form 4 insider transactions across 3 companies since 2013. The most recent filing, for FBRX, was dated Aug 27, 2026. Across all open-market trades the lifetime net is +$37.8K, making them a net buyer over the disclosed history. 9 SEC filings were submitted jointly with Sorrento Therapeutics, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

3

Total Filings

30

Lifetime Open-Market Net

$37.8K

Filer Profile

Reported Address
C/O WOMEN FIRST HEALTH CARE
5355 MIRA SORRENTO PLACE STE. 700
SAN DIEGO, CA 92121-3825
Related Filers
Sorrento Therapeutics, Inc. — 9 joint filings, latest 2014-10-09
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
FBRX Director — $76.99 — $0 4 2026-08-27
Oncternal Therapeutics, Inc. (ONCT) Delisted Chief Financial Officer 7,138 $0.53 $3.8K $37.8K 18 2024-02-15
Sorrento Therapeutics, Inc. (SRNE) Delisted See Remarks — $0.00 — $0 2 2014-10-09

Recent Filings

30 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-27 FBRX Disp (D) — $0 EDGAR
2026-06-02 FBRX Grant (A) — $0 EDGAR
2025-03-21 FBRX Grant (A) — $0 EDGAR
2024-09-19 FBRX Grant (A) — $0 EDGAR
2024-02-15 Oncternal Therapeutics, Inc. (ONCT) Delisted Grant (A) — $0 EDGAR
2024-01-05 Oncternal Therapeutics, Inc. (ONCT) Delisted Tax (F) −8,868 -$4.4K EDGAR
2023-10-04 Oncternal Therapeutics, Inc. (ONCT) Delisted Mixed — $0 EDGAR
2023-07-05 Oncternal Therapeutics, Inc. (ONCT) Delisted Tax (F) −7,069 -$2.5K EDGAR
2023-04-14 Oncternal Therapeutics, Inc. (ONCT) Delisted Buy (P) +30,000 $9.0K EDGAR
2023-02-23 Oncternal Therapeutics, Inc. (ONCT) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 30
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.